Key result
Phenotyping, biomarkers, and AI are required to overcome heterogeneous responses in HF regenerative medicine.
Why the study?
Outcome variability challenges therapeutic innovation, and determinants separating success from failure in achieving disease rescue with emergent regenerative biotherapies remain largely unknown.
Highlights the need for phenotype-based patient selection and deep learning to identify responders to regenerative biotherapies in heart failure.
Answers are grounded in this paper and cite their sources.
Does not support clinical adoption of regenerative heart failure therapies; leaves open optimal phenotype and biomarker strategies.
Risk of outcome variability challenges therapeutic innovation. Selection of the most suitable candidates is predicated on reliable response indicators. Especially for emergent regenerative biotherapies, determinants separating success from failure in achieving disease rescue remain largely unknown. Accordingly, (pre)clinical development programs have placed increased emphasis on the multi-dimensional decoding of repair capacity and disease resolution, attributes defining responsiveness. To attain regenerative goals for each individual, phenotype-based patient selection is poised for an upgrade guided by new insights into disease biology, translated into refined surveillance of response regulators and deep learning-amplified clinical decision support.
No takes yet. Share an insight, caveat, or question.
Yamada et al. (2021) conducted a review in Heart failure. Regenerative therapy was evaluated. Phenotype-based patient selection, biomarker-guided individualization, and artificial intelligence-empowered decision support are required to overcome heterogeneous therapeutic responses in regenerative medicine for heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: